C-C motif chemokine 28 Antibodies

C-C motif chemokine 28 (CCL28)

Chemotactic activity for resting CD4, CD8 T-cells and eosinophils.

Binds to CCR3 and CCR10 and induces calcium mobilization in a dose-dependent manner.

.

Gene Information

Human
Gene Name:	CCL28
Uniprot:	Q9NRJ3
Entrez:	56477

Family

Belongs to:
intercrine beta (chemokine CC) family

Alternative Names

CCL28; chemokine (C-C motif) ligand 28; MEC; member 28; MGC71902; Protein CCK1; VIC

Molecular Weight

Mass (kDA):
14.28 kDA

Genomic Context

Human
Location:	5p12
Sequence:	5; NC_000005.10 (43356972..43412391, complement)

Tissue Specificity

Preferentially expressed by epithelial cells of diverse tissues including normal and pathological colon, salivary gland, mammary gland, trachea and rectum. Also found in prostate, spleen, thyroid, psoriasis skin and in lower levels in peripheral blood leukocytes, small intestine, Peyer patches, stomach and normal skin.

Subcellular Localizations

Secreted.

Diseases

• Inflammation
• Cholangiocarcinoma
• Tissue Adhesions
• Asthma
• Malignant Neoplasms
• Neoplasms
• Dermatitis, Atopic
• Dermatitis
• Inflammatory Bowel Diseases
• Colitis
• Intestinal Diseases
• Cholera
• Dog Diseases

• Lung Diseases
• Dermatologic Disorders
• Ulcer
• Tumor Angiogenesis
• Infective Disorder
• Malignant Neoplasm Of Breast
• Mammary Neoplasms

Interacting Proteins

• CCL11
• CCL17
• CCL21
• CCL26
• CCL5

• CXCL10
• CXCL12
• DDI1
• PF4
• PSMA3

• STUB1

Pathways

• Cell Adhesion
• Chemotaxis
• Pathogenesis
• Immune Response
• Localization
• Secretion
• Lactation
• Lymphocyte Migration
• Angiogenesis
• Chemokine Production
• Tropism
• Inflammatory Response
• Sensitization

• Mrna Transcription
• Cell Migration
• Diapedesis
• Hypersensitivity
• Response To Virus
• Adaptive Immune Response
• Protein Secretion

PTMs

• Phosphorylation

• Cleavage

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CCL28

Boster Bio: Best Uses Of The CCL28 Marker

This article will discuss Boster Bio's neutralizing antibodies against CCL5, their affinity for SARS/CoV-2 Delta and the various ways this reagent could be used. We will also cover Boster's optimization process. You'll be able to use this product in your research after reading this article. Whether you're working on a clinical trial or a research project, you'll have a greater understanding of the Boster Bio CCL28 marker.

Boster Bio's CCL5 neutralizing Antibody

A neutralizing anti-CCL5 antibody is an immunochemical tool that can be used in cancer research. It targets the C-C motif that is responsible for the synthesis and secretion of this chemokine. This antibody can also block the activity of other chemicals, such as IP3R and PLC. It also prevents the growth of ER Calcium stores. CCL5 inhibitors decrease the viability rate of cancer cells, according to research. The antibody also reduces the number viable cells, inhibits colony growth, and makes them more resistant to cisplatin.

The first round involved tumor tissue samples from patients diagnosed with high-grade serous or ovarian cancer. The patients underwent an intraoperative fast biopsy to confirm the diagnosis. The patient samples were then processed by primary antibodies against vimentin and a-SMA. As a control, the mouse monoclonal antibodies were used. The cells were cultured with serum-free medium. The treated supernatant is referred to as CM* while the control medium is referred as the negative controls.

CCL5 is a powerful tool in cancer research. CCL5 is a biomarker in breast cancer. It can be used to stop its migration and is therefore one way to treat the disease. CCL5 is also produced in cancer-associated macrophages, which stimulates cancer growth. However, the metabolic interactions between cancer cells and macrophages are unclear. CCL5 also promotes cell migration and increases the expression of glycolytic enzymes MDA-MB-231 cells and MCF-7 cells. Therefore, an anti-CCL5 antibody can help researchers study the role of CCL5 in cancer metabolism.

Antibodies that neutralize COVID-2 such as CA521FALA are highly effective in fighting the disease. This antibody is highly specific and binds all three RBDs on the spike simultaneously. It has a long half life, making it a promising therapeutic option. It has also shown promising clinical trials against COVID-19. However, neutralizing antibodies may not always be based upon published structures. It is imperative to study full length antibodies in order to determine if they are effective.

Its affinity for SARS-CoV-2 Delta strain

Using a novel immobilized N protein from the SARS-CoV-2 virus, the researchers determined the binding affinity of this chemokine to SARS-CoV-2 N protein. These two chemokines interact on the cell surfaces. Apart from binding the N protein, N has been shown to bind 64 human Cytokines, including CCL11a, CCL26, CXCL12b and CCL14. All of these cytokines have nanomolar affinity.

Boster Bio's neutralizing antibodies bind to the SARS/CoV-2 Delta strain. The antibody produced by the second dose of this vaccine reduced the severity of delta infection in mice. The CCL28 marker is 13 times more effective against the SARS-CoV-2 Delta strain than that of the Pfizer vaccination. However, further research is required to confirm Boster Bio's CCL28-likeness to the SARS CoV-2 Delta Strain.

Infected cells were able to show the affinity of CCL28 for SARS/CoV-2 Delta strain. CellTrace Violet was used to stain infected cells with SARS-2 Delta strain. 50 ml of RPMI-1640 containing 4% low immunogenic serum and 5 x 104 Jurkat effector cell were then added. The co-cultured cells were then given serial dilutions with the indicated human MAbs.

The new marker SARS-CoV-2 has been designed to detect ACE2 receptors on SARS-CoV-2. Its ability of detecting the SARS-2 Delta strain was previously difficult to achieve. However, the team behind it have now developed an extremely sensitive and accurate test that can be used to help doctors determine the risk of contracting the disease. This important disease is the focus of this research.

Researchers also reported a tennucleotide gene deletion in C23L that is a new genetic indicator for Group 1 Brazilian vaCV. The deletion is due to the presence in this gene of a premature stop codon, which is common among VACVBR strains. These results suggest that the C23L gene mutation may be a useful genetic marker to identify non-virulent Brazilian VACV strains. This deletion could also be useful in detecting new strains.

Its optimization

The Boster Microplate Reader allows you to measure the absorbance in samples. The multichannel pipettes allow you to dispense from 0.5 ml to 1 ml of aqueous solutions. Boster Bio offers product credit when you share your results. The Boster Microplate Reader can measure absorbance to 450nm. A multichannel pipette for larger sample volumes is recommended.

Its uses

The CCL28 mark is a protein with many uses. It is often used for research on the immune response in an infected body. It has been shown that it has strong homing capabilities and orchestrates lymphocyte trafficking and function. It has both immunomodulatory and chemotactic capabilities. It interacts well with CCR10 & CCR3 suggesting a dual role in immune response.

CCL28 has been shown to be more effective than CCL19 at promoting Ag-specific cellular or humoral immune responses. CCL28 is expressed by both human and mouse mucosal tissues. This cytokine appears to be produced by epithelial cell and has many functions in immune responses. It may also play a role in vaccine development. In this instance, the CCL28 mark is a tremendous help in the fight to genital herpes.

CCL28 is an immunotherapy marker that is commonly used to develop vaccines targeting tumors. These vaccines contain DNA that codeliveries CCL28 gene-specific cellular responses. The CCL28-DNA vaccines stimulate immune response protection in the body, and boost tumor-fighting immunity. CCL28 IL vaccine has been found to increase T-cell dependent phagocytosis.

Researchers have demonstrated that CCL28 plays an important role in the pathogenesis of post-viral asthma. Hence, it may be a good target for new asthma therapeutics. Further research is needed to determine the biologic activity. The CCL28 markers may have many uses. Next, we need to identify which drugs target it and how they work. And what are the benefits of this marker?

CCL28 and CCL27 share a common origin, according to the phylogenetic tree. They share the CCR10 receptor and may represent the earliest CC chemokine in mammals. CCL28 shares a C-terminus that is similar to histatin, CCL27. This supports the idea that CCL28 evolved into an antimicrobial and chemokine.